Development of Novel Silyl Cyanocinnamic Acid Derivatives as Metabolic Plasticity Inhibitors for Cancer Treatment

Keyphrases

• Cancer Treatment 100%
• Monocarboxylate Transporter 1 (MCT1) 100%
• Metabolic Plasticity 100%
• Silyl 100%
• Acid Derivatives 100%
• Inhibition Properties 66%
• Efficacy Study 33%
• Mitochondrial Metabolism 33%
• In Vitro Study 33%
• Systemic Efficacy 33%
• Hydroxycinnamic Acids 33%
• Metabolic Pathway 33%
• Anticancer Activity 33%
• Cyano 33%
• In Vitro Effect 33%
• Cell Proliferation Inhibition 33%
• Tumor Xenograft 33%
• Lactate Uptake 33%
• Glycolytic Metabolism 33%
• Colorectal Cancer Cells 33%
• Homology Modeling 33%
• Uptake Studies 33%
• Cancer Cell Proliferation 33%
• Docking Studies 33%
• Novel Anticancer Agent 33%
• Transporter Inhibitor 33%
• WiDr 33%
• Inhibitor Docking 33%
• Systemic Toxicity Study 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Monocarboxylate Transporter 100%
• Efficacy Study 50%
• Anticarcinogen 50%
• Coumaric Acid 50%
• Colorectal Carcinoma 50%
• Lactic Acid 50%
• Neoplasm 50%
• Anticancer Drug 50%